Browse
Search
2021-069-E Health-NC Div of Public Health vaccine agreement addendum
OrangeCountyNC
>
Board of County Commissioners
>
Contracts and Agreements
>
General Contracts and Agreements
>
2020's
>
2021
>
2021-069-E Health-NC Div of Public Health vaccine agreement addendum
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
2/9/2021 1:43:47 PM
Creation date
2/9/2021 12:59:21 PM
Metadata
Fields
Template:
Contract
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
10
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
DocuSign Envelope ID: DB33BBBD-6336-4169-BA22-EC80FA1149C6 <br /> Page 4 of 6 <br /> 4) Include a description of enhanced outreach activities vaccinate priority populations, <br /> hard-to-reach, and marginalized populations, and how community partners are to be <br /> included in the outreach. <br /> IV. Performance Measures/Reporting Requirements: <br /> 1. Report vaccine administration data on all vaccine recipients. <br /> 2. Track and report COVID-19 vaccine transfers and vaccine wastage/spoilage occurrences to the <br /> Immunization Branch when they occur. <br /> 3. Train staff on COVID-19 vaccine administration, management, inventory, and reporting <br /> requirements as required by Immunization Branch and the CDC. <br /> V. Performance Monitoring and Ouality Assurance: <br /> 1. The Immunization Branch will monitor this activity through reporting data, tracking the number of <br /> doses administered, and handling of the vaccine inventory are the key monitoring metrics. If issues <br /> are noted with performance (i.e., delays in vaccination, failure to adhere to storage and handling <br /> requirements), a consultation via telephone or on-site follow-up from the Program Monitor shall <br /> occur. <br /> 2. The LHD is required to track non-compliance issues by corrective action plans. The Program <br /> Monitor shall make every effort to work with the LHD on strategies to resolve the issue and <br /> corrective action plans. If the plan is not followed and the LHD remains out of compliance after <br /> intervention and resources from DPH, vaccine shipments may be suspended until the LHD can be <br /> brought back into compliance. <br /> VI. Funding Guidelines or Restrictions: <br /> 1. Requirements for pass-through entities: In compliance with 2 CFR §200.331 —Requirements for <br /> pass-through entities, the Division of Public Health provides Federal Award Reporting Supplements <br /> to the Local Health Department receiving federally funded Agreement Addenda. <br /> a. Definition: A Supplement discloses the required elements of a single federal award. <br /> Supplements address elements of federal funding sources only; state funding elements will <br /> not be included in the Supplement. Agreement Addenda(AAs) funded by more than one <br /> federal award will receive a disclosure Supplement for each federal award. <br /> b. Frequency: Supplements will be generated as the Division of Public Health receives <br /> information for federal grants. Supplements will be issued to the Local Health Department <br /> throughout the state fiscal year. For federally funded AAs, Supplements will accompany the <br /> original AA. If AAs are revised and if the revision affects federal funds, the AA Revisions <br /> will include Supplements. Supplements can also be sent to the Local Health Department even <br /> if no change is needed to the AA. In those instances, the Supplements will be sent to provide <br /> newly received federal grant information for funds already allocated in the existing AA. <br /> 2. The LHD must submit its planned expenditures by completing Attachment A, which is to include the <br /> dollar amount and a budget justification statement for each budget category. <br /> Revised July 2019 <br />
The URL can be used to link to this page
Your browser does not support the video tag.